Dr. Reddy’s Laboratories Limited RDY on Friday launched its generic Semaglutide Injection in Canada. This move is significant as it positions Dr. Reddy’s among the first companies to introduce this ...
Indian pharma major Dr Reddy's Laboratories has received regulatory approval from Health Canada to sell the first generic version of Novo Nordisk's blockbuster diabetes-cum-weight-loss drug Ozempic ...
Dr. Reddy's Laboratories Limited (RDY Quick Quote RDY - Free Report) reported fourth-quarter fiscal 2025 earnings of 22 cents per American Depositary Share (ADS), which beat the Zacks Consensus ...
Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...
Dr. Reddy’s Laboratories RDY is a major player in the generic drugs markets. The company reports its financial performance under three operating segments — Global Generics, Pharmaceutical Services & ...
Canada became the first G7 jurisdiction to authorize a generic semaglutide injection, with rapid launch post–Notice of Compliance indicating mature commercial readiness and supply-chain execution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results